PAK4 and triple-negative breast carcinoma: Additionally, KPT-9274, a dual-specific inhibitor targeting PAK4 and nicotinamide phosphoribosyltransferase, effectively suppressed the growth, survival, and migration of triple-negative breast cancer 41, 42, kidney cancer 43, acute myeloid leukemia 44, and ovarian cancer cells 45.